[go: up one dir, main page]

MY194461A - N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases - Google Patents

N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases

Info

Publication number
MY194461A
MY194461A MYPI2018000570A MYPI2018000570A MY194461A MY 194461 A MY194461 A MY 194461A MY PI2018000570 A MYPI2018000570 A MY PI2018000570A MY PI2018000570 A MYPI2018000570 A MY PI2018000570A MY 194461 A MY194461 A MY 194461A
Authority
MY
Malaysia
Prior art keywords
benzylpiperidin
pyrazin
piperazine
antagonists
muscarinic receptor
Prior art date
Application number
MYPI2018000570A
Inventor
Nicole Harriott
Nicholas Pagano
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MY194461A publication Critical patent/MY194461A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Provided herein are small molecule compounds of the following formula (I): (I) or a stereoisomer, tautomer, solvate, ester, prodrug, or pharmaceutically acceptable salt thereof, wherein A, B, C, L1, L2, R1, R2, R3, R4, R5, w, x, y and z are as defined herein. Methods for treating diseases/disorders by antagonizing muscarinic receptors, including specifically antagonizing muscarinic receptor 4 (M4), are also provided.
MYPI2018000570A 2015-11-06 2016-11-04 N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases MY194461A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562252179P 2015-11-06 2015-11-06
US201662275708P 2016-01-06 2016-01-06
PCT/US2016/060659 WO2017079641A1 (en) 2015-11-06 2016-11-04 N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases

Publications (1)

Publication Number Publication Date
MY194461A true MY194461A (en) 2022-11-30

Family

ID=57349137

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018000570A MY194461A (en) 2015-11-06 2016-11-04 N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases

Country Status (22)

Country Link
US (2) US11033539B2 (en)
EP (1) EP3371164B1 (en)
JP (2) JP6917989B2 (en)
KR (1) KR20180073685A (en)
CN (1) CN108349936B (en)
AU (1) AU2016348524B2 (en)
BR (1) BR112018008630A2 (en)
CA (1) CA3001873A1 (en)
CL (1) CL2018001217A1 (en)
CO (1) CO2018004800A2 (en)
ES (1) ES2915266T3 (en)
HK (1) HK1253029A1 (en)
IL (1) IL258862B (en)
MA (1) MA43168A (en)
MX (1) MX386148B (en)
MY (1) MY194461A (en)
PE (1) PE20181010A1 (en)
PH (1) PH12018500940A1 (en)
SA (1) SA518391518B1 (en)
SG (1) SG11201803757UA (en)
TN (1) TN2018000130A1 (en)
WO (1) WO2017079641A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050083T2 (en) 2015-11-06 2020-11-30 Hoffmann La Roche Indolin-2-one derivatives
SG11201803757UA (en) * 2015-11-06 2018-06-28 Neurocrine Biosciences Inc N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
WO2019032654A1 (en) 2017-08-08 2019-02-14 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019079410A1 (en) 2017-10-17 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CA3079617A1 (en) 2017-10-20 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019089676A1 (en) 2017-10-31 2019-05-09 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
EP3732163A4 (en) 2017-12-20 2021-07-14 Vanderbilt University MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4
CA3090130A1 (en) * 2018-02-02 2019-08-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
PE20251292A1 (en) 2018-03-08 2025-05-14 Incyte Corp DIOLIC AMINOPYRAZINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020051153A1 (en) 2018-09-04 2020-03-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine m1 receptor antagonists
CN119241444A (en) * 2019-06-17 2025-01-03 德西费拉制药有限责任公司 Aminopyrimidine amide autophagy inhibitors and methods of use thereof
JP2022549227A (en) * 2019-09-17 2022-11-24 バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for use in treating medical disorders
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
ES2983860T3 (en) 2019-12-06 2024-10-25 Neurocrine Biosciences Inc Muscarinic receptor 4 antagonists and methods of use
CN111072551A (en) * 2019-12-30 2020-04-28 上海睿瓦科技有限公司 Method for preparing piperidine amine by catalytic hydrogenation one-step method
EP4100410A1 (en) * 2020-02-05 2022-12-14 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
KR20240019340A (en) * 2021-06-11 2024-02-14 뉴로내슨트, 아이엔씨. Methods and compositions for lipid preparations of lipophilic small molecule therapy of heterocyclic type
WO2023010078A1 (en) * 2021-07-30 2023-02-02 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
KR20250116664A (en) * 2022-11-16 2025-08-01 번위 테라퓨틱스 인코포레이티드 TYK2 inhibitor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622976A (en) * 1991-12-31 1997-04-22 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
GB9313201D0 (en) * 1993-06-25 1993-08-11 Fujisawa Pharmaceutical Co New heterocyclic compounds
US5700801A (en) * 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
TR200001399T2 (en) * 1997-11-18 2000-11-21 Teijin Limited Cyclic amine derivatives and their use as drugs.
DE60023878T2 (en) * 1999-05-18 2006-07-20 Teijin Ltd. REMEDIES AND PREVENTION FOR CHEMOKIN-ASSOCIATED DISEASES
AU5786300A (en) * 1999-09-22 2001-04-24 Schering Corporation Muscarinic antagonists
KR100708247B1 (en) * 1999-12-08 2007-04-16 데이진 가부시키가이샤 Cyclic Amine Cr5 Receptor Antagonist
US6410566B1 (en) * 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
WO2003062234A1 (en) 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Quinoxaline compounds
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AU2003300902A1 (en) * 2002-12-13 2004-07-09 Smithkline Beecham Corporation Piperidine derivatives as CCR5 antagonists
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
EP1904446A2 (en) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2007075629A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
EP1997805A1 (en) * 2007-06-01 2008-12-03 Commissariat à l'Energie Atomique Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
JP2013028538A (en) * 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd Novel amide derivative
EA027800B1 (en) 2011-11-25 2017-09-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors
US20150259649A1 (en) * 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
HK1207317A1 (en) * 2012-11-20 2016-01-29 霍夫曼-拉罗奇有限公司 Substituted 1,6-naphthyridines
US10179770B2 (en) 2013-03-18 2019-01-15 Genoscience Pharma Quinolines derivatives as novel anticancer agents
JP6272832B2 (en) 2013-04-04 2018-01-31 武田薬品工業株式会社 Heterocyclic compounds
US9611223B2 (en) * 2013-09-11 2017-04-04 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US9745271B2 (en) * 2014-03-20 2017-08-29 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
SG11201803757UA (en) * 2015-11-06 2018-06-28 Neurocrine Biosciences Inc N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases

Also Published As

Publication number Publication date
MX386148B (en) 2025-03-18
CL2018001217A1 (en) 2018-08-03
TN2018000130A1 (en) 2019-10-04
SG11201803757UA (en) 2018-06-28
SA518391518B1 (en) 2021-06-13
KR20180073685A (en) 2018-07-02
JP2018531981A (en) 2018-11-01
US20180325887A1 (en) 2018-11-15
CA3001873A1 (en) 2017-05-11
MA43168A (en) 2018-09-12
MX2018005215A (en) 2018-08-01
CN108349936A (en) 2018-07-31
ES2915266T3 (en) 2022-06-21
EP3371164A1 (en) 2018-09-12
EP3371164B1 (en) 2022-03-16
PH12018500940A1 (en) 2018-12-17
JP6917989B2 (en) 2021-08-11
CO2018004800A2 (en) 2018-10-31
CN108349936B (en) 2021-10-01
US20210338653A1 (en) 2021-11-04
BR112018008630A2 (en) 2018-10-30
PE20181010A1 (en) 2018-06-26
IL258862B (en) 2021-02-28
JP2021050243A (en) 2021-04-01
HK1253029A1 (en) 2019-06-06
IL258862A (en) 2018-06-28
AU2016348524A1 (en) 2018-05-17
WO2017079641A1 (en) 2017-05-11
AU2016348524B2 (en) 2021-01-28
US11033539B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
SA518391518B1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
PH12020500125A1 (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009763A (en) 3-(1-OXO-5-(PIPERIDIN-4-IL)ISOINDOLIN-2-IL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF.
MX2020005363A (en) Heterocyclic compounds as prmt5 inhibitors.
SA519401322B1 (en) Heteroaryl carboxamide compounds as inhibitors of receptor-interacting serine/threonine protein kinase 2
MX373102B (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PH12016501440A1 (en) Novel heterocyclic compounds
MX354175B (en) Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation.
EA201691428A1 (en) BICYCLIC HETEROCYCLIC DERIVATIVES AS IRAK4 INHIBITORS
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
HK1231471A1 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
PE20141167A1 (en) PYRIDOPYRAZINES SUBSTITUTED AS NOVEL PTK INHIBITORS
PH12017501423A1 (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
SI3102573T1 (en) Substituted thiazole or oxazole p2x7 receptor antagonists
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
EA201891038A1 (en) MUSCARINE RECEPTOR 4 ANTAGONISTS AND METHODS OF THEIR APPLICATION
NZ801355A (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
UA109736C2 (en) POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS)